Insmed Announces CFO Transition as Company Faces New Financial Horizons#United_States#Bridgewater#Insmed#Brinsupri#Sara_Bonstein
Insmed Announces CFO Transition as Company Faces New Financial Horizons
Insmed has announced the stepping down of CFO Sara Bonstein, effective October 30, 2026. The company assures continuation of financial plans amid this leadership change.
third-news.com
October 5, 2026 at 11:11 AM
Insmed Announces CFO Transition as Company Faces New Financial Horizons#United_States#Bridgewater#Insmed#Brinsupri#Sara_Bonstein
Insmed to Showcase Key Findings from Its Respiratory Portfolio at ERS Congress 2026#USA#Bridgewater#Insmed#ARIKAYCE#Brinsupri
Insmed to Showcase Key Findings from Its Respiratory Portfolio at ERS Congress 2026
Insmed will present crucial data from its respiratory portfolio, including significant findings from the Phase 3b ENCORE study on ARIKAYCE and other therapies, at the ERS Congress 2026.
third-news.com
September 3, 2026 at 11:16 AM
Insmed to Showcase Key Findings from Its Respiratory Portfolio at ERS Congress 2026#USA#Bridgewater#Insmed#ARIKAYCE#Brinsupri
Japan Approves BRINSUPRI® for Treating Non-Cystic Fibrosis Bronchiectasis, A Major Milestone for Patients#Japan#Tokyo#Insmed#Bronchiectasis#Brinsupri
Japan Approves BRINSUPRI® for Treating Non-Cystic Fibrosis Bronchiectasis, A Major Milestone for Patients
Insmed's BRINSUPRI® (brensocatib) receives approval in Japan for treating non-cystic fibrosis bronchiectasis, marking a breakthrough for patients suffering from this chronic condition.
third-news.com
August 24, 2026 at 11:06 AM
Japan Approves BRINSUPRI® for Treating Non-Cystic Fibrosis Bronchiectasis, A Major Milestone for Patients#Japan#Tokyo#Insmed#Bronchiectasis#Brinsupri
BRINSUPRI® (brensocatib) Approved by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
https://www.byteseu.com/2303324/
BRINSUPRI® (brensocatib) Approved by Japan’s Ministry of Health, Labour and …
https://www.byteseu.com/2303324/
BRINSUPRI® (brensocatib) Approved by Japan’s Ministry of Health, Labour and …
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - Bytes Europe
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a
www.byteseu.com
August 24, 2026 at 11:39 AM
BRINSUPRI® (brensocatib) Approved by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
https://www.byteseu.com/2303324/
BRINSUPRI® (brensocatib) Approved by Japan’s Ministry of Health, Labour and …
https://www.byteseu.com/2303324/
BRINSUPRI® (brensocatib) Approved by Japan’s Ministry of Health, Labour and …
#Insmed is joining forces with an organisation representing people living with the #chroniclungdisorder #bronchiectasis to carry out a large-scale, #realworldstudy of its recently approved therapy #Brinsupri in the #US.
pharmaphorum.com/news/insmed-...
pharmaphorum.com/news/insmed-...
August 13, 2026 at 8:09 AM
#Insmed is joining forces with an organisation representing people living with the #chroniclungdisorder #bronchiectasis to carry out a large-scale, #realworldstudy of its recently approved therapy #Brinsupri in the #US.
pharmaphorum.com/news/insmed-...
pharmaphorum.com/news/insmed-...
#$INSM delivered a standout Q2 with $425.5M revenue driven by $309M BRINSUPRI sales. Company raised 2026 guidance and long-term peak sales to $14B+. notreload.xyz/xy/insm-jump...
Insmed (INSM) Jumps 30% as BRINSUPRI Launch Crushes It
Insmed delivered a standout Q2 with $425.5M revenue driven by $309M BRINSUPRI sales. Company raised 2026 guidance and long-term peak sales to $14B+.
notreload.xyz
August 6, 2026 at 4:55 PM
#$INSM delivered a standout Q2 with $425.5M revenue driven by $309M BRINSUPRI sales. Company raised 2026 guidance and long-term peak sales to $14B+. notreload.xyz/xy/insm-jump...
Insmed Crushes Estimates, Nears Profitability as BRINSUPRI Revenue Soars to $309M https://signalbloom.ai/news/INSM/insmed-crushes-estimates-nears-profitability-as-brinsupri-revenue-soars-to-309m $INSM #Earnings via @signalbloom.ai
August 6, 2026 at 11:06 AM
Insmed Crushes Estimates, Nears Profitability as BRINSUPRI Revenue Soars to $309M https://signalbloom.ai/news/INSM/insmed-crushes-estimates-nears-profitability-as-brinsupri-revenue-soars-to-309m $INSM #Earnings via @signalbloom.ai
Insmed's Second-Quarter 2026 Financial Performance Outshines Expectations with Impressive Revenue Growth#United_States#Bridgewater#Insmed#ARIKAYCE#Brinsupri
Insmed's Second-Quarter 2026 Financial Performance Outshines Expectations with Impressive Revenue Growth
Insmed reports significant revenue growth in Q2 2026, driven by thriving sales of BRINSUPRI and ARIKAYCE. The company sets ambitious revenue guidance for 2026.
third-news.com
August 6, 2026 at 11:21 AM
Insmed's Second-Quarter 2026 Financial Performance Outshines Expectations with Impressive Revenue Growth#United_States#Bridgewater#Insmed#ARIKAYCE#Brinsupri
#INSM Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-s963p9xax2cq.html
https://www.stocktitan.net/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-s963p9xax2cq.html
Insmed expects three lead programs to generate over $14B in peak sales
BRINSUPRI generated $309.2M, up 49% from Q1, while ARIKAYCE reached $116.3M. Insmed plans a Japan review of ARIKAYCE data in H2 2026.
www.stocktitan.net
August 6, 2026 at 11:01 AM
#INSM Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
https://www.stocktitan.net/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-s963p9xax2cq.html
https://www.stocktitan.net/news/INSM/insmed-reports-second-quarter-2026-financial-results-and-provides-s963p9xax2cq.html
Back in June 4th, i had created my 1st Rule34 NSFW of Strawberry from Magiberry rides a dildo by my OC Ovnitdesri from Brinsupri® and had i ever have a Field PG M5 then my new NSFW will be served in the future
Enjoy!
Simulcast from @noitteaaxsmdxt18.bsky.social
#firstpornofcharacter
#magiberrynsfw
Enjoy!
Simulcast from @noitteaaxsmdxt18.bsky.social
#firstpornofcharacter
#magiberrynsfw
July 18, 2026 at 9:53 PM
Back in June 4th, i had created my 1st Rule34 NSFW of Strawberry from Magiberry rides a dildo by my OC Ovnitdesri from Brinsupri® and had i ever have a Field PG M5 then my new NSFW will be served in the future
Enjoy!
Simulcast from @noitteaaxsmdxt18.bsky.social
#firstpornofcharacter
#magiberrynsfw
Enjoy!
Simulcast from @noitteaaxsmdxt18.bsky.social
#firstpornofcharacter
#magiberrynsfw
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com
nexttech-news.com
January 11, 2026 at 12:08 AM
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
The top advertisers on CBS
Boycott them
Do it for colbert
Do it for fair media they have crushed
1 Austedo XR Austedo, tablets
2 Attruby (acoramidis)
3 INGREZZA
4 SKYRIZI
5 Claritin
6 Tremfya (guselkumab)
7 Ashley Homestore
8 Neuriva, suppliments for the brain
9 Fasenra
10 Brinsupri
Boycott them
Do it for colbert
Do it for fair media they have crushed
1 Austedo XR Austedo, tablets
2 Attruby (acoramidis)
3 INGREZZA
4 SKYRIZI
5 Claritin
6 Tremfya (guselkumab)
7 Ashley Homestore
8 Neuriva, suppliments for the brain
9 Fasenra
10 Brinsupri
CBS Advertisers - Stop Media Bias Now
stopmediabiasnow.com
May 23, 2026 at 3:52 PM
The top advertisers on CBS
Boycott them
Do it for colbert
Do it for fair media they have crushed
1 Austedo XR Austedo, tablets
2 Attruby (acoramidis)
3 INGREZZA
4 SKYRIZI
5 Claritin
6 Tremfya (guselkumab)
7 Ashley Homestore
8 Neuriva, suppliments for the brain
9 Fasenra
10 Brinsupri
Boycott them
Do it for colbert
Do it for fair media they have crushed
1 Austedo XR Austedo, tablets
2 Attruby (acoramidis)
3 INGREZZA
4 SKYRIZI
5 Claritin
6 Tremfya (guselkumab)
7 Ashley Homestore
8 Neuriva, suppliments for the brain
9 Fasenra
10 Brinsupri
#$INSM +4.15% [Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.] notreload.xyz/morgan-stanl...
Morgan Stanley Boosts Insmed on Strong Brinsupri Outlook
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
notreload.xyz
March 30, 2026 at 1:33 PM
#$INSM +4.15% [Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.] notreload.xyz/morgan-stanl...
$INSM +6.3% [BRINSUPRI, the first & only FDA-approved oral treatment for Non-Cystic Fibrosis Bronchiectasis (NCFB), is available for adults/children 12+. This first-in-class DPP1 inhibitor reduces exacerbations for ~500k US patients. Available by prescription.] investor.insmed.com/2025-08-12-F...
August 12, 2025 at 5:22 PM
$INSM +6.3% [BRINSUPRI, the first & only FDA-approved oral treatment for Non-Cystic Fibrosis Bronchiectasis (NCFB), is available for adults/children 12+. This first-in-class DPP1 inhibitor reduces exacerbations for ~500k US patients. Available by prescription.] investor.insmed.com/2025-08-12-F...
Fri news: Lilly’s Omvoh achieves 91% Crohn’s remission at 3 years. AZ’s Calquence combo wins FDA nod. Insmed’s $1B Brinsupri sales projection. ACIP meeting delayed. Biohaven charts comeback by taking obesity path. —https://bit.ly/3JeBlY5
February 20, 2026 at 5:20 PM
Fri news: Lilly’s Omvoh achieves 91% Crohn’s remission at 3 years. AZ’s Calquence combo wins FDA nod. Insmed’s $1B Brinsupri sales projection. ACIP meeting delayed. Biohaven charts comeback by taking obesity path. —https://bit.ly/3JeBlY5
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech News, where innovation meets insight. Discover the latest breakthroughs, get exclusive updates, and connect with a global network of future-focused thinkers. Unlock tomorrow’s trends today: read more, subscribe to our newsletter, and become part of the NextTech community at NextTech-news.com
nexttech-news.com
January 11, 2026 at 12:08 AM
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug. Elevate your perspective with NextTech…
📈 Trending on DRUGDOCS® in August 2025:
1️⃣ Zegfrovy® – oral EGFR exon 20 inhibitor for advanced NSCLC
2️⃣ Brinsupri® – the first FDA-approved DPP1 inhibitor for bronchiectasis
3️⃣ Tyenne® – IL-6 blocker for RA, GCA, and juvenile idiopathic arthritis
🔍 Discover the science at DRUGDOCS® → drugdocs.com
1️⃣ Zegfrovy® – oral EGFR exon 20 inhibitor for advanced NSCLC
2️⃣ Brinsupri® – the first FDA-approved DPP1 inhibitor for bronchiectasis
3️⃣ Tyenne® – IL-6 blocker for RA, GCA, and juvenile idiopathic arthritis
🔍 Discover the science at DRUGDOCS® → drugdocs.com
September 4, 2025 at 6:49 PM
📈 Trending on DRUGDOCS® in August 2025:
1️⃣ Zegfrovy® – oral EGFR exon 20 inhibitor for advanced NSCLC
2️⃣ Brinsupri® – the first FDA-approved DPP1 inhibitor for bronchiectasis
3️⃣ Tyenne® – IL-6 blocker for RA, GCA, and juvenile idiopathic arthritis
🔍 Discover the science at DRUGDOCS® → drugdocs.com
1️⃣ Zegfrovy® – oral EGFR exon 20 inhibitor for advanced NSCLC
2️⃣ Brinsupri® – the first FDA-approved DPP1 inhibitor for bronchiectasis
3️⃣ Tyenne® – IL-6 blocker for RA, GCA, and juvenile idiopathic arthritis
🔍 Discover the science at DRUGDOCS® → drugdocs.com